Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;28(9):1844-1857.
doi: 10.1038/s41593-025-02032-y. Epub 2025 Aug 11.

Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice

Affiliations

Potentiation of mitochondrial function by mitoDREADD-Gs reverses pharmacological and neurodegenerative cognitive impairment in mice

Antonio C Pagano Zottola et al. Nat Neurosci. 2025 Sep.

Abstract

Many brain disorders involve mitochondrial alterations, but owing to the lack of suitable tools, the causal role of mitochondrial dysfunction in pathophysiological processes is difficult to establish. Heterotrimeric guanine nucleotide-binding (G) proteins are key regulators of cell functions, and they can be found within mitochondria. Therefore, we reasoned that the activation of stimulatory mitochondrial G proteins (Gs) could rapidly promote the activity of the organelle and possibly compensate for bioenergetic dysfunction. Here, we show that a mitochondria-targeted recombinant designer receptor exclusively activated by designer drugs (mitoDREADD-Gs) can acutely trigger intramitochondrial signaling to increase mitochondrial membrane potential and oxygen consumption. In vivo activation of mitoDREADD-Gs abolished memory alterations in cannabinoid-treated mice and in two mouse models of Alzheimer's disease and frontotemporal dementia. Thus, mitoDREADD-Gs enables the establishment of causal relationships between mitochondria and biological or disease-related processes and represents an innovative potential therapeutic approach for disorders associated with mitochondrial impairment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics and inclusion statement: One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community.

References

    1. Mattson, M. P., Gleichmann, M. & Cheng, A. Mitochondria in neuroplasticity and neurological disorders. Neuron 60, 748–766 (2008). - PubMed - PMC - DOI
    1. Chu, C. T. Mitochondria in neurodegeneration. Curr. Opin. Physiol. 26, 100532 (2022). - PubMed - PMC - DOI
    1. Rossignol, D. A. & Frye, R. E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol. Psychiatry 17, 290–314 (2012). - PubMed - DOI
    1. Manji, H. et al. Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 13, 293–307 (2012). - PubMed - DOI
    1. Anglin, R. E., Garside, S. L., Tarnopolsky, M. A., Mazurek, M. F. & Rosebush, P. I. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J. Clin. Psychiatry 73, 506–512 (2012). - PubMed - DOI

MeSH terms

LinkOut - more resources